Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation.

Current drug targets - 1 Jan 2026

Huang Xiang, Zhang Shimei, Wang Linjuan, Qiu Yue, Zhao Min, Chen Qiufang

Abstract excerpt

INTRODUCTION: Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, and the MET exon 14 skipping mutation is a key oncogenic driver, which promotes tumor progression and provides a new direction for precision therapy. METHODS: A systematic search of English-language literature and clinical trial data related to the MET exon 14 skipping mutation from 2020-2025 was performed to summarize the...

Read the complete abstract on PubMed

Topics

Humans
Proto-Oncogene Proteins c-met
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Exons
Mutation

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Biomarkers, Tumor

Precision Medicine

Genomics

Protein Kinase Inhibitors

High-Throughput Nucleotide Sequencing

Molecular Targeted Therapy

Animals

Drug Resistance, Neoplasm

Antineoplastic Agents

Source

Identifiers

PMID: 41588951
DOI: 10.2174/0113894501409916251103161912

Genes

MET

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MET Exon 14 Skipping Mutation in NSCLC: From Genomic Discovery to Biomarker-Guided Therapeutic Innovation.PMID 41588951Read ↗

Lung Cancer with MET exon 14 Skipping Mutation: Genetic Feature, Current Treatments, and Future ChallengesSemantic proximity Read ↗

Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer.Semantic proximity Read ↗

Detection of MET exon 14 skipping mutations in non-small cell lung cancer: overview and community perspective.Semantic proximity Read ↗

Pitfalls in Detecting MET Exon 14 Skipping Variants by DNA- and RNA-Based Next-Generation Sequencing Technologies in a Large Real-World Cohort and Results of the First Multinational External Quality Assessment Schemes.Semantic proximity Read ↗

MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.Semantic proximity Read ↗

Expert consensus on the diagnosis and treatment of non-small cell lung cancer with MET alteration.Semantic proximity Read ↗

MET exon 14 skipping mutations in non-small-cell lung cancer a 3 years screening experienceSemantic proximity Read ↗

[MET Exon 14 Skipping Mutations in Non-small Cell Lung Cancer].Semantic proximity Read ↗

Characterization of Non-Small-Cell Lung Cancers With MET Exon 14 Skipping Alterations Detected in Tissue or Liquid: Clinicogenomics and Real-World Treatment Patterns.Semantic proximity Read ↗

MET Exon 14 Skipping Mutations in Non-Small-Cell Lung Cancer: An Overview of Biology, Clinical Outcomes, and Testing Considerations.Semantic proximity Read ↗

From knowledge to action: The journey toward targeting the MET pathway via MET exon 14 skippingSemantic proximity Read ↗

Incidence and PD-L1 Expression of MET 14 Skipping in Chinese Population: A Non-Selective NSCLC Cohort Study Using RNA-Based SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.